Cargando…

Clinical relevance of the 21-gene Recurrence Score(®) assay in treatment decisions for patients with node-positive breast cancer in the genomic era

In contemporary management of early-stage breast cancer, clinical decisions regarding adjuvant systemic therapy are increasingly made after considering both genomic assay results and clinico-pathologic features. Genomic information augments the prognostic information gleaned from clinico-pathologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mamounas, Eleftherios P., Russell, Christy A., Lau, Anna, Turner, Michelle P., Albain, Kathy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102296/ https://www.ncbi.nlm.nih.gov/pubmed/30155517 http://dx.doi.org/10.1038/s41523-018-0082-6

Ejemplares similares

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
por: Hassan, Saima, et al.
Publicado: (2022)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer
por: Frazier, Thomas G., et al.
Publicado: (2015)

The Role of the 21-Gene Recurrence Score(®) Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
por: Yordanova, Mariya, et al.
Publicado: (2022)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS
por: Sulayman, Nadiyah, et al.
Publicado: (2012)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

Surgical management of the breast and axilla after neoadjuvant treatment: the role of sentinel node biopsy
por: Mamounas, EP
Publicado: (2009)

Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
por: Alkushi, Abdulmohsen, et al.
Publicado: (2020)

The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database
por: Choi, In Sil, et al.
Publicado: (2020)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
por: Wu, San-Gang, et al.
Publicado: (2019)

Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor–positive, Node-positive Breast Cancer
por: Brufsky, Adam M.
Publicado: (2014)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
por: Gunia, Sommer R., et al.
Publicado: (2012)

Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
por: Chen, Wei-Rong, et al.
Publicado: (2019)

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes
por: Li, Guan-Qiao, et al.
Publicado: (2023)

Performance of Automated Dissection on Formalin-Fixed Paraffin-Embedded Tissue Sections for the 21-Gene Recurrence Score Assay
por: Qi, Peng, et al.
Publicado: (2020)

Surgeon and medical oncologist peer network effects on the uptake of the 21‐gene breast cancer recurrence score assay
por: Zipkin, Ronnie, et al.
Publicado: (2021)

Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
por: Chen, Jonathan, et al.
Publicado: (2018)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
por: Hannouf, Malek B, et al.
Publicado: (2012)

Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals
por: Martínez del Prado, Purificación, et al.
Publicado: (2018)

Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database
por: Jung, Jiwoong, et al.
Publicado: (2022)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
por: Lee, Moo Hyun, et al.
Publicado: (2015)

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
por: Jayasekera, Jinani, et al.
Publicado: (2021)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Young-Onset Colon Cancer and Recurrence Risk by Gene Expression
por: Chang, George J, et al.
Publicado: (2020)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma
por: Bartsch, Fabian, et al.
Publicado: (2020)

Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction
por: Wang, Changjun, et al.
Publicado: (2022)

Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score
por: Paik, Soonmyung, et al.
Publicado: (2021)

Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer()
por: Howard, Candace M., et al.
Publicado: (2020)

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
por: Park, Seho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_psle9r9ht11erqeeuua35l440q